KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to -$4.0 million.

  • Emergent BioSolutions' Change in Account Payables rose 8260.87% to -$4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$30.0 million, marking a year-over-year decrease of 33.44%. This contributed to the annual value of -$33.0 million for FY2024, which is 41132.08% down from last year.
  • According to the latest figures from Q3 2025, Emergent BioSolutions' Change in Account Payables is -$4.0 million, which was up 8260.87% from -$10.4 million recorded in Q2 2025.
  • Emergent BioSolutions' Change in Account Payables' 5-year high stood at $31.0 million during Q1 2023, with a 5-year trough of -$23.0 million in Q3 2024.
  • Its 5-year average for Change in Account Payables is -$3.0 million, with a median of -$4.5 million in 2021.
  • Its Change in Account Payables has fluctuated over the past 5 years, first crashed by 120000.0% in 2021, then surged by 31088.44% in 2023.
  • Emergent BioSolutions' Change in Account Payables (Quarter) stood at -$5.1 million in 2021, then soared by 56.86% to -$2.2 million in 2022, then tumbled by 222.73% to -$7.1 million in 2023, then crashed by 43.66% to -$10.2 million in 2024, then soared by 60.78% to -$4.0 million in 2025.
  • Its Change in Account Payables stands at -$4.0 million for Q3 2025, versus -$10.4 million for Q2 2025 and -$5.4 million for Q1 2025.